You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 229 Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Checkpoint blockade therapy
229 Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy

 

Online download statistics by month:

Online download statistics by month: November 2020 to October 2024

AbstractFullPdf
Nov 202081013
Dec 202030014
Jan 2021802
Feb 2021804
Mar 20216007
Apr 20211202
May 2021909
Jun 2021008
Jul 2021107
Aug 2021005
Sep 2021006
Oct 202114022
Nov 20218011
Dec 2021604
Jan 20221801
Feb 20221401
Mar 20221600
Apr 20223205
May 202240019
Jun 20223206
Jul 20222703
Aug 2022607
Sep 20221203
Oct 20224006
Nov 20221402
Dec 20222201
Jan 20231600
Feb 20232603
Mar 20231601
Apr 2023402
May 20231202
Jun 20233803
Jul 20232102
Aug 2023400
Sep 2023200
Oct 20231205
Nov 20231202
Dec 20232800
Jan 2024801
Feb 2024600
Mar 20241802
Apr 2024801
May 20241802
Jun 20241302
Jul 20241402
Aug 20242603
Sep 20241401
Oct 20241405
Total8400207